The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.0M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 695K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

16 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Novel dabigatran derivatives with a fluorine atom at the C-2 position of the terminal benzene ring: Design, synthesis and anticoagulant activity evaluation.EBI
Shanghai Institute of Technology
Design, synthesis, anticoagulant activity evaluation and molecular docking studies of a class of N-ethyl dabigatran derivatives.EBI
Shanghai Institute of Technology
Molecular design, synthesis and anticoagulant activity evaluation of fluorinated dabigatran analogues.EBI
Shanghai Institute of Technology
Discovery of bis-aryl urea derivatives as potent and selective Limk inhibitors: Exploring Limk1 activity and Limk1/ROCK2 selectivity through a combined computational study.EBI
Shanghai Institute of Technology
Design, synthesis and structural exploration of novel fluorinated dabigatran derivatives as direct thrombin inhibitors.EBI
Shanghai Institute of Technology
Discovery of potent and selective urea-based ROCK inhibitors: Exploring the inhibitor's potency and ROCK2/PKA selectivity by 3D-QSAR, molecular docking and molecular dynamics simulations.EBI
Shanghai Institute of Technology
Molecular modeling studies of atorvastatin analogues as HMGR inhibitors using 3D-QSAR, molecular docking and molecular dynamics simulations.EBI
Shanghai Institute of Technology
Design, synthesis and biological evaluation of combretastatin A-4 sulfamate derivatives as potential anti-cancer agents.EBI
Shanghai Institute of Technology
Computer-aided discovery of phenylpyrazole based amides as potent S6K1 inhibitors.EBI
Shanghai Institute of Technology
Discovery of novel pyrrolo[2,3-b]pyridine derivatives bearing 4-oxoquinoline moiety as potential antitumor inhibitor.EBI
Shanghai Institute of Technology
Discovery of (S)-6-methoxy-chroman-3-carboxylic acid (4-pyridin-4-yl-phenyl)-amide as potent and isoform selective ROCK2 inhibitors.EBI
Shanghai Institute of Technology
Discovery of novel acylhydrazone neuraminidase inhibitors.EBI
Shanghai Institute of Technology
Discovery of Novel Neuraminidase Inhibitors by Structure-Based Virtual Screening, Structural Optimization, and Bioassay.EBI
Shanghai Institute of Technology
Molecular modeling studies, synthesis and biological evaluation of dabigatran analogues as thrombin inhibitors.EBI
Shanghai Institute of Technology
Design, synthesis and biological evaluation of novel oseltamivir derivatives as potent neuraminidase inhibitors.EBI
Shanghai Institute of Technology
Discovery of (E)-1-amino-4-phenylbut-3-en-2-ol derivatives as novel neuraminidase inhibitors.EBI
Shanghai Institute of Technology